MTS Health Investors LLC has sold Celerion Holdings Inc to Court Square Capital Partners. Financial terms weren’t announced. Celerion’s management team will continue to own a minority stake. Celerion, of Lincoln, Nebraska, is a clinical research organization that provides clinical trial solutions to pharmaceutical and biotechnology clients conducting early clinical research throughout North America, Europe, and Asia. Lazard Middle Market LLC served as financial adviser, while McDermott Will & Emery LLP acted as legal adviser to Celerion on the transaction.
(New York, NY) November 14, 2017 – MTS Health Investors, LLC (“MTS”), a healthcare-focused private equity firm, announced that its portfolio company Celerion Holdings, Inc. (“Celerion”) has partnered with Court Square Capital Partners (“Court Square”). Court Square is investing in partnership with the Celerion management team, who will continue to own a minority interest in the Company. Terms of the transaction were not disclosed.
Celerion is a premier clinical research organization that provides comprehensive clinical trial solutions to pharmaceutical and biotechnology clients conducting early clinical research throughout North America, Europe, and Asia. The Company serves its clients through a global network of facilities with a focus on applied translational medicine. MTS completed its majority investment in Celerion in October of 2014.
“We are proud to have supported and participated in Celerion’s growth and successes over the past three years,” said Curtis Lane, Senior Managing Director of MTS. “It is gratifying to see our collaboration with the Celerion team culminate in a partnership that will bring new opportunities to the Company and also deliver an outstanding return to our investors.”
“MTS has been an invaluable partner for Celerion. Their deep industry expertise and extensive network of resources were instrumental to helping us execute on our growth plan and expand our capabilities,” said Susan Thornton, CEO of Celerion. “By partnering with Court Square, we will continue to provide unmatched service to our existing customers, drive value to our clients and pursue additional growth opportunities.”
Lazard Middle Market LLC served as sole financial advisor, and McDermott Will & Emery LLP served as legal advisor to Celerion on the transaction.
MTS Health Investors, LLC (“MTS”) makes equity investments in companies that operate within the services sectors of the healthcare industry. MTS focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. MTS manages over $700 million in investments and is currently investing out of its fourth fund. MTS is based in New York City and invests in companies throughout the United States.
For more information, please email us at MTSHealthInvestorsIR@mtspartners.com.